Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
For 43 assays, more than 80% of samples provided concentrations within the dynamic range of the assay.
Why it matters
In this exploratory study of cerebrospinal fluid, 30 biomarkers differed significantly across cognitive groups, and 10 proteins including pTau217, total tau, neurofilament light and GFAP distinguished people with mild cognitive impairment who progressed to dementia from those who did not, with ptau217 performing best. The authors say these markers could help personalize treatment and stratify people for therapeutic studies, but this is an exploratory biomarker study, not a treatment or cure.
-
We found significant main effects between GFAP groups and age, diagnosis of AD, diagnosis of VaD, MoCA, sex, CRP and BMI.
Why it matters
This study found that higher GFAP levels, a marker of neuroinflammation, were linked to older age and to diagnoses of Alzheimer's and vascular dementia. It describes relationships between inflammation and clinical features but does not test any treatment.
-
Alzheimer’s disease (AD) is the most prevalent cause of dementia, characterized by progressive cognitive decline, amyloid-β (Aβ) plaques, and neurofibrillary tangles composed of hyperphosphorylated tau protein.
Why it matters
This review describes how glycosylation, the attachment of glycans to proteins or lipids, influences tau stability, Aβ processing, synaptic integrity, and neuroinflammation. It notes that dysregulated glycosylation patterns in brains and cerebrospinal fluid of Alzheimer's patients suggest biomarker potential and novel therapeutic targets.
-
In 2021, LOAD demonstrated a substantially higher global burden than EOAD: incidence cases (8,455,150 [95% UI: 5,818,063-11,461,560] vs. 1,381,906 [894,768-1,963,453]), mortality cases (1,879,291 [471,472-4,968,222] vs. 73,386 [14,059-232,170]), and DALYs (32,558,570 [14,907,368-71,154,572] vs. 3,774,117 [1,696,439-8,881,154]).
Why it matters
This analysis shows that late-onset Alzheimer's disease and other dementias had a much higher global burden than early-onset forms in 2021, and this gap is projected to remain by 2035. It highlights the need for different strategies targeting early-onset and late-onset dementia.
-
In 4 of 5 patients treated with lecanemab or donanemab and who had moderate or severe ARIA-E, Aβ PET signal decreased significantly more in regions that had been involved with ARIA-E. Greater regional Aβ PET signal reduction in areas involved by ARIA-E may reflect enhanced local Aβ clearance, reduced tracer binding site availability, impaired glymphatic flow from immune complex deposition, or other mechanisms.
Why it matters
In 4 of 5 patients with moderate or severe ARIA-E after lecanemab or donanemab, amyloid PET signal dropped more in the regions affected by ARIA-E. This is a small observational finding about ARIA-E and does not establish any benefit for treating or preventing Alzheimer's disease.
-
Alzheimer's disease (AD), the most prevalent form of dementia, is neuropathologically defined by the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau.
Why it matters
This review describes how microglia and astrocytes change in Alzheimer's disease and can both protect and harm the brain through inflammation and other processes. It frames glial cells as active participants in disease progression but does not report a treatment or cure.
-
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease associated with accumulation of amyloid beta peptides and intracellular neurofibrillary tangles formed by hyperphosphorylated Tau.
Why it matters
This review discusses how autophagy and mitophagy relate to Alzheimer's disease, noting that impaired autophagy may account for the accumulation of protein aggregates and that Alzheimer-related proteins such as APOE4, TREM2, PSEN1/2, APP and Tau can regulate autophagy. It is a review of existing evidence and does not report a new treatment, cure or prevention for patients.
-
Accurate differentiation of Alzheimer's disease (AD), frontotemporal dementia (FTD), and healthy control (HC) is critical for early diagnosis and intervention of brain disorders.
Why it matters
A deep learning framework using EEG functional connectivity achieved about 90% accuracy in distinguishing Alzheimer's disease and frontotemporal dementia from healthy controls. This is a diagnostic classification study and does not provide a treatment, cure, or prevention.
-
Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by hallmark pathologies such as amyloid-beta (Aβ) plaque accumulation, tau hyperphosphorylation, and progressive neuronal dysfunction.
Why it matters
This review highlights the understudied roles of oligodendrocytes and their precursor cells in Alzheimer's disease, including demyelination, impaired remyelination and links to cholesterol and lipid metabolism. It summarizes emerging evidence and does not report a treatment, cure or prevention.
-
Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies.
Why it matters
This review found limited and inconsistent information on early Alzheimer's disease prevalence, diagnosis, and treatment in Asia, Australasia, and Pacific nations, despite rapidly aging populations. Although new amyloid-targeting therapies are approved in some countries, the best diagnostic pathway is not established and healthcare systems may struggle to respond.
-
Parkinson's disease (PD), as a common neurodegenerative disorder, its associated mild cognitive impairment (PD-mild cognitive impairment, PD-MCI) is a key prodromal stage in the progression to PD-dementia (PDD).
Why it matters
This review summarizes multimodal biomarkers for early diagnosis of mild cognitive impairment in Parkinson's disease. It is about diagnosis only and does not test any treatment, cure or prevention.
-
Lewy body dementia (LBD) is a neurodegenerative disorder characterized by a combination of progressive dementia and spontaneous parkinsonian symptoms.
Why it matters
This is a review of Lewy body dementia that analyses disease hallmarks, genetic risk factors, clinical features and treatment strategies, and evaluates the role of animal models in this research. It proposes directions for future Lewy body dementia therapeutic management and does not report any treatment, cure or prevention for Alzheimer's disease.
-
Alzheimer disease is a multifactorial neurodegenerative disorder characterized by amyloid-beta plaques, tau tangles, and neuroinflammation, with emerging evidence highlighting a potential role for brain lymphatic dysfunction.
Why it matters
This review proposes lymphovenous anastomosis surgery as a way to improve clearance of brain waste products, but it reports only preliminary supporting evidence and calls for more research on protocols, mechanisms, and safety. It is not an established treatment, and no outcomes in Alzheimer's patients are reported.
-
Alzheimer's disease (AD) is the most common cause of dementia and is a growing public health challenge.
Why it matters
This review discusses evidence that T and B lymphocytes of the adaptive immune system, not just the innate immune system, are involved in the neuroinflammation of Alzheimer's disease. It proposes that targeting adaptive immunity might lead to new treatments, but no such treatment has been tested or proven here.
-
The 3D Nested Hierarchical Transformer model helped to accurately diagnose Alzheimer disease based on structural brain MRI scans.
Why it matters
This study found that a 3D Nested Hierarchical Transformer model accurately diagnosed Alzheimer disease from structural MRI scans, but false negatives occurred consistently across models in patients with atypical disease and preserved cognition. It is a diagnostic study and does not test any treatment, cure, or prevention.
-
Biomarkers serve as a quantitative measure of brain injury and may predict cognitive outcome after cardiac arrest.
Why it matters
In cardiac arrest survivors, Alzheimer's disease blood markers measured in the first days after arrest showed at best small links to cognitive performance at six months, while the nerve injury marker neurofilament light showed somewhat stronger links. This means these Alzheimer's markers did not clearly predict cognitive outcome after cardiac arrest in this study.
-
With a burgeoning dementia burden driven by unique demographic, genetic, and socioeconomic factors of East Asia, the region has made significant investments in understanding disease mechanisms, developing biomarkers, and exploring therapeutic approaches.
Why it matters
This editorial highlights the current landscape of Alzheimer's disease and related dementias research in East Asia, including advances in biomarkers and diagnostic strategies. It does not present new findings on treating, curing, or preventing the disease.
-
Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG).
Why it matters
This study trained machine learning models on brain electromagnetic data from MEG and EEG to tell apart healthy controls, people with mild cognitive impairment and people with Alzheimer's disease, with the best result reaching about 72.63% accuracy. It is a diagnostic classification study and does not test any treatment, cure or prevention.
-
Symptom extraction across the 7 domains achieved high accuracy with AUROCs ranging from 0.97 to 0.99.
Why it matters
This study found that a large language model could extract Alzheimer's disease and related dementia symptoms from text with high accuracy and predict diagnosis. The approach has the potential to assist with differential diagnosis and to facilitate clinical trials and research studies of dementia.
-
Aggression in patients with dementia poses significant caregiving and clinical issues.
Why it matters
This work compares two ways of combining audio and visual signals to classify aggression in dementia patients, and found that Late Fusion gave better accuracy, recall, F1-score and ROC-AUC, while Early Fusion gave slightly better precision. It is a technical classification study and does not test any treatment, cure or prevention for Alzheimer's disease.
-
Epidemiological evidence has revealed an associative link between sepsis survivorship and increased risk of dementia, particularly Alzheimer's disease (AD).
Why it matters
In a mouse model of Alzheimer's amyloidosis, sepsis led to higher hippocampal amyloid-beta and anxiety indices at 3 months in both male and female AD-model mice. This is early animal research, so it does not yet show how sepsis affects Alzheimer's disease in people.
-
Retrograde bias better predicted tau progression than anterograde bias, but our best-fitting biophysical models incorporate the mixed effects of both retrograde- and anterograde-directed spread, with notable tau-strain-specific differences.
Why it matters
In eleven mouse models of tauopathy, mathematical models of retrograde and mixed-direction spread fit tau progression better than anterograde spread, with differences between tau strains. This is animal modeling work about how tau spreads, not a treatment or prevention for people.
-
AD patients had significantly higher AD-RAI (0.91 ± 0.25) and more pronounced hippocampal atrophy (0.36 ± 0.09) compared to MCI and HC (P 0.9 for distinguishing BPSD from non-BPSD patients.
Why it matters
An MRI-based quantitative analysis system distinguished Alzheimer's disease from mild cognitive impairment and healthy controls and identified behavioral symptoms. This supports diagnosis but does not provide a treatment, cure, or prevention.
-
Between 1990 and 2021, ADOD incidence, prevalence, deaths, and DALYs increased significantly.
Why it matters
This global analysis found that the burden of Alzheimer's disease and other dementias increased significantly between 1990 and 2021, with metabolic factors and high fasting plasma glucose having the most influence in 2021. The authors say early screening, especially for elderly women, is crucial and that policymakers must act to reverse this trend.
-
Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer's disease (AD).
Why it matters
This paper assesses the potential for ocular biomarker testing to become standard practice for early detection of Alzheimer's disease. It describes technical and practical requirements for adoption and does not test any treatment, cure, or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The Clinical Diagnosis of Alzheimer's Disease
- MIND diet adherence and cognitive function in Alzheimer's disease: Mediating roles of neural oscillatory markers from resting‐state EEG
- Healthy Cardiovascular Status Attenuates the Detrimental Association Between Osteosarcopenic Adiposity and Alzheimer's Disease‐Related Dementia: A UK Biobank Cohort Study
- Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease
- The Humanistic and Economic Burden of Alzheimer's Disease
- Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism
- Lecanemab autorizado para tratamiento del Alzhéimer en pacientes que tienen una o ninguna copia de ApoE4: una reacción adversa grave limita su uso
- Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index
- Spatial navigation, physical activity, and Alzheimer disease biomarkers
- Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment